Infutraze (Zinc Chloride, Potassium Iodide, Sodium Selenite, Copper Chloride Dihydrate, Manganese Chloride Tetr)

Each component acts as a cofactor for specific enzymes. Zinc supports DNA synthesis and immune function; iodine is essential for thyroid hormone production; selenium contributes to antioxidant enzymes; copper participates in iron metabolism and connective‑tissue formation; manganese is required for carbohydrate and lipid metabolism. Delivered intravenously, they become immediately available for cellular processes.

The dose of Infutraze is individualized by the prescribing clinician based on the patient’s serum trace‑element levels, the composition of the total parenteral nutrition regimen, and clinical condition. No fixed dosing schedule is provided; the healthcare professional calculates the appropriate amount to achieve target concentrations while avoiding excess.

Safety data for Infutraze in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision. The prescriber must evaluate the clinical situation and consider alternative options if appropriate.

To order Infutraze, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Infutraze provides a balanced blend of five essential trace elements in a single intravenous formulation, which can simplify compounding compared with using separate single‑element solutions. Its composition aligns with European parenteral nutrition guidelines, offering comparable bioavailability while reducing the risk of incompatibility that may arise when mixing multiple individual additives.

Infutraze must be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required by the administration protocol.

Infutraze is administered intravenously, typically added to a compatible parenteral nutrition bag or infused as a separate line according to the prescriber’s instructions. The infusion rate is adjusted based on the patient’s clinical status and laboratory monitoring to ensure safe delivery of the trace elements.

Serious risks include anaphylactic reactions, severe electrolyte imbalances (especially excess copper or zinc), and selenium toxicity, which can manifest as respiratory distress or gastrointestinal symptoms. Prompt recognition and management of these events are essential, and regular monitoring of serum trace‑element levels helps mitigate these risks.

Infutraze should be avoided in patients with known hypersensitivity to any of its components, those with severe copper or zinc overload, and individuals receiving high‑dose concurrent trace‑element supplements that could cause cumulative toxicity. Clinical judgment is required for patients with significant hepatic or renal impairment.